Septerna (SEPN) SVP receives 80,000 stock options with four-year vesting

Rhea-AI Filing Summary

Septerna, Inc. officer Uwe Klein, SVP, Biological Sciences, received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $25.41 per share and were awarded on February 6, 2026.

According to the vesting schedule, 2/48 of the option shares will vest and become exercisable on March 1, 2026, with the remaining shares vesting in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Klein’s continued service with Septerna.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Uwe

(Last) (First) (Middle)

C/O SEPTERNA, INC.

250 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Septerna, Inc. [ SEPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Biological Sciences

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.41	02/06/2026		A		80,000		(1)	02/05/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney

	/s/ Mark A. Wilson, Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Septerna (SEPN) report for Uwe Klein?

Septerna reported a stock option grant to SVP, Biological Sciences, Uwe Klein. He received options for 80,000 shares of common stock on February 6, 2026, as reflected in a Form 4 insider trading report.

How many Septerna (SEPN) shares are covered by Uwe Klein’s stock options?

The stock option grant to Uwe Klein covers 80,000 shares of Septerna common stock. These options give him the right to purchase that number of shares if and when they vest and become exercisable.

What is the exercise price of Uwe Klein’s Septerna (SEPN) stock options?

The exercise price for Uwe Klein’s stock options is $25.41 per share. This means he can buy Septerna common shares at $25.41 once the options vest and he chooses to exercise them.

When do Uwe Klein’s Septerna (SEPN) stock options start vesting?

The options start vesting on March 1, 2026. On that date, 2/48 of the total shares vest, with the remaining portion vesting in 46 substantially equal monthly installments, subject to his continued service.

What is the vesting schedule for Uwe Klein’s Septerna (SEPN) option grant?

The vesting schedule provides that 2/48 of the 80,000 shares vest on March 1, 2026. The remaining shares vest in 46 substantially equal monthly installments on each monthly anniversary, assuming Uwe Klein remains in continuous service.

Is Uwe Klein’s Septerna (SEPN) stock option grant held directly or indirectly?

The Form 4 reports that the 80,000 stock options are held with direct ownership. There is no indication of an intermediary entity or indirect beneficial ownership in the provided disclosure.